The HIV V2179-181 (HXB2 numbering) tripeptide mediates binding to α4β7 integrin, which is responsible for GALT homing. The exact role of V2 in viral transmission and replication and possible clinical correlates are still unclear. We aimed to assess V2 variability in naive HIV-1 infected patients and its association with clinical and viro-immunological features.
Gp120 sequences were obtained from 323 subjects newly diagnosed with HIV infection; V2 regions were evaluated for length, potential N-linked glycosylation sites (PNGs), net charge (NC) and tripeptide motif at residues 179-181. A possible association with HIV subtype, R5/X4 co-receptor tropism (CRT) (FPR 10%), duration of HIV infection (based on ambiguous nucleotides frequency in RT/PR, e.g. ≤0.2% ambiguity=recent infection) and patients’ variables (sex; age; risk factor; stage; baseline viro-immunological data) was explored.
Patients were mainly males (85%), MSM (54%), median age 35 yrs (range 27-44), 41% with a recent HIV infection, AIDS in 15%, 67% infected with subtype B, and 82% with R5 variants. V2 data are shown in Table 1. No association was found between patients’ features and V2 length, PNGs or NC. LDV was the most common V2179-181 tripeptide (41.2%), followed by LDI (24.5%); Asp180 was highly conserved in both B and non-B strains (99%). 59.8% and 40.2% of B vs non-B sequences (p≤0.001) had a Leu179. Val181 was detected in 62% and 38% of B/non-B (p=0.04) while Ile181 in 73% vs 27% of B/non-B subtypes (p=0.034), respectively. No correlation between CRT and V2179-181 variants, or presence of LDV vs LDI motif was observed. Patients with L-strains had more frequently a recent infection (65% vs 37% in non-L, p=0.01); no other association between patient features and 179L/non-L variants was found. Conversely, patients with Val181 were younger (median age 32.3 vs 37.8, p=0.004), mainly MSM (63% vs 41%, p≤0.001), with higher CD4 (p=0.04), and an earlier stage at diagnosis (C3 1% vs 10%, p≤0.001) than patients with other variants. A multivariate analysis confirmed correlation with risk factor and stage.
Our results show a certain variability in V2 structure, including the α4β7 binding tripeptide, described as highly conserved. Due to potential therapeutic implications, further studies confirming our findings of a possible association of V2 features with viro-immunological characteristics are warranted.